← All countries · Americas
100%
MCV1
2024 · Administrative (country-reported)
86.7%
DTP3
2024 · Administrative (country-reported)
100%
IPV complete
2024 · Administrative (country-reported)
100%
HepB3
2024 · Administrative (country-reported)
0
Measles cases
2024 reported
0
Pertussis (whooping cough) cases
2024 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | —% · Administrative (country-reported) | — | too few points | no data |
| DTP1First dose of diphtheria-tetanus-pertussis | 100%2024 · Administrative (country-reported) | 100% | too few points | D · poor |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 86.7%2024 · Administrative (country-reported) | 86.7% | too few points | D · poor |
| IPV1First dose of inactivated polio vaccine | 100%2024 · Administrative (country-reported) | 100% | too few points | D · poor |
| IPV completeInactivated polio vaccine, complete primary series | 100%2024 · Administrative (country-reported) | 100% | too few points | D · poor |
| MCV1First dose of measles-containing vaccine | 100%2024 · Administrative (country-reported) | 100% | too few points | D · poor |
| MCV2Second dose of measles-containing vaccine | 100%2024 · Administrative (country-reported) | 100% | too few points | D · poor |
| RCV1First dose of rubella-containing vaccine | 100%2024 · Administrative (country-reported) | 100% | too few points | D · poor |
| HepB3Third dose of hepatitis B vaccine | 100%2024 · Administrative (country-reported) | 100% | too few points | D · poor |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 100%2024 · Administrative (country-reported) | 100% | too few points | D · poor |
| PCV1Pneumococcal conjugate vaccine, first dose | 100%2024 · Administrative (country-reported) | 100% | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 86.7%2024 · Administrative (country-reported) | 86.7% | too few points | D · poor |
| RotaCRotavirus vaccine, complete series | 86.7%2024 · Administrative (country-reported) | 86.7% | too few points | D · poor |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02024 | —per 1,000,000 total population | too few points | D · poor |
| Rubella all countries · vaccine evidence | 02024 | —per 1,000,000 total population | too few points | D · poor |
| Congenital rubella syndrome all countries · vaccine evidence | 02024 | —per 10,000 live births | too few points | D · poor |
| Mumps all countries · vaccine evidence | 02024 | —per 1,000,000 total population | too few points | D · poor |
| Pertussis (whooping cough) all countries · vaccine evidence | 02024 | —per 1,000,000 total population | too few points | D · poor |
| Diphtheria all countries · vaccine evidence | 02024 | —per 1,000,000 total population | too few points | D · poor |
| Tetanus (total) all countries · vaccine evidence | 02024 | —per 1,000,000 total population | too few points | D · poor |
| Neonatal tetanus all countries · vaccine evidence | 02024 | —per 1,000 live births | too few points | D · poor |
| Polio (paralytic) all countries · vaccine evidence | 02024 | —per 1,000,000 <15 population | too few points | D · poor |
| Yellow fever all countries · vaccine evidence | 02024 | —per 1,000,000 total population | too few points | D · poor |
| Invasive meningococcal disease all countries · vaccine evidence | 02024 | —per 1,000,000 total population | too few points | D · poor |
| Typhoid all countries · vaccine evidence | 02024 | —per 1,000,000 total population | too few points | D · poor |
National schedule (latest WHO listing)
Show the schedule (18 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| DTAPDTaP (acellular) vaccine | 4 | Y5 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M3 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | Risk group(s) | Children whose mother didn't received the Tdap vaccine during the 22 weeks of pregnancy |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M5 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M12 | General/routine | |
| DTIPVDT-IPV (Diphtheria and tetanus toxoid and IPV) vaccine | 5 | Y14 | General/routine | |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 1 | Y10 | HPV administered to females and males | boys and girls. before 2024 it was vaccinated just girls. In january 2024 boys were incorporated in the vaccine schedule |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 2 | +M6 | HPV administered to females and males | boys and girls. before 2024 it was vaccinated just girls. In january 2024 boys were incorporated in the vaccine schedule |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M14 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 2 | Y14 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 1 | M14 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | Y3 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | M3 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | M5 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | M12 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | W6-W9 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M3 | General/routine | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | 22 weeks of pregnancy |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.